Bioethicists Advocate Cost Criterion For Coverage With Evidence Development
This article was originally published in The Gray Sheet
Executive Summary
Pricier medical technologies might be better candidates for Medicare coverage conditioned on collection of evidence than less costly products, National Institutes of Health bioethicists suggest